marvelbiosciences

We re-develop off-patent, known and proven drugs for new applications. Our model is to reduce cost, time, and risk and so, bring our assets to market faster.

[marvelbiosciences @marvelbiosci]

Marvel's $MRVL news today marks the 3rd independent preclinical #autism ASD model in which MB-204 has demonstrated robust efficacy. The study was conducted through the independent FRAXA Drug Validation Initiative, further strengthening the scientific validation of the program

[marvelbiosciences @marvelbiosci]

Thank you to FRAXA Research Foundation for your continued leadership in advancing Fragile X syndrome research and supporting the global scientific community. At Marvel, we're proud to contribute to this important field through the development of MB-204.
https://t.co/Kr3MdbXMbu

[marvelbiosciences @marvelbiosci]

Marvel Biosciences ($MRVL | $MBCOF) announces positive preclinical data demonstrating MB-204 restored behavioural and cognitive function toward normal levels in validated Fragile X Syndrome (Fmr1 knockout) mouse model, with durable carry-over effects. PR: https://t.co/1MVgc2g4nK

[Rare Diseases @CheckOrphan]

Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X - For More Information Visit https://t.co/DdoZ1QqCpq @marvelbiosci #Fragile_X_Syndrome #Rare_Diseases #Orphan_Drugs

[Frontiers - Neurology @FrontNeurol]

New Research: Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United States https://t.co/gSnXT254Gi #FrontiersIn #Neurology

[marvelbiosciences @marvelbiosci]

Marvel Biosciences Financing Opportunity
Phase 1 clinical trials approaching, multiple international patents and strong preclinical data, Marvel is entering a pivotal stage in the development of its lead therapeutic candidate, MB-204.
Contact [email protected] for info.

[marvelbiosciences @marvelbiosci]

Marvel Biosciences $MRVL $MBCOF Announces Financing to Advance MB-204 Toward Phase 1 Clinical Trials; up to $3 million, proceeds expected to support the Phase 1 clinical development of its lead therapeutic candidate, MB-204.

Read the full announcement: https://t.co/E5RvhZ1rUz

[marvelbiosciences @marvelbiosci]

EY Biotech Beyond Borders Report 2026

In this EY Biotech Beyond Borders report, long-range observations find the industry’s fundamentals remain very strong. In 2025, the biotech industry hit US$232b in revenues; Biopharma raised US$68.5b, up 11% in 2024.

https://t.co/uh6Br36urT

[marvelbiosciences @marvelbiosci]

LIFE SCIENCES UPDATE: Momentum rebuilds in life sciences, powering a strong start to 2026

Link to full report: https://t.co/tk9X8yXyhD

[marvelbiosciences @marvelbiosci]

We're proud to announce that new autism research from Marvel's $MRVL scientific collaborators at the iBraiN Institute will be presented at the 3rd European Purine Meeting in Bordeaux, France, on July 1–3, 2026.

Link to full announcement: https://t.co/luTOaZVei4

[marvelbiosciences @marvelbiosci]

🎥Research Radius Interview
CEO Rod Matheson and CSO Mark Williams share insights into Marvel's lead, patented asset, MB-204, the Company's development roadmap, and opportunities ahead as $MRVL advances toward clinical milestones and into Phase 1.
Link: https://t.co/HlgHT1vsx4

[Martin Gagel @RadiusResearch]

🔬 @Marvelbiosci (TSXV: $MRVL | OTC: $MBCOF) – MB-204 Clinical Development Update

CEO Rod Matheson and President Dr. Mark Williams review the clinical roadmap for MB-204, targeting neurological and neurodevelopmental disorders including #autism spectrum disorder, #Rettsyndrome and #FragileXsyndrome, and discuss next steps as the company prepares to advance toward Phase 1 trials.

▶️ Watch the full interview here ➝ https://t.co/MhSRt9MCnq

#MarvelBiosciences #Biotech #Neurology #ClinicalTrials #AutismResearch #DrugDevelopment #LifeSciences

[marvelbiosciences @marvelbiosci]

Marvel Biosciences $MRVL is pleased to announce that it has received a Notice of Allowance for its Australian composition-of-matter patent application covering MB-204, the Company’s lead therapeutic candidate.

Link to press release: https://t.co/cRQAJUrXMi

[marvelbiosciences @marvelbiosci]

Biotech Funding 2026 Tracker: Latest Raises, Rounds and R&D Momentum
https://t.co/pQYSsrCCIf

[marvelbiosciences @marvelbiosci]

Rett syndrome study highlights potential for personalized treatments

https://t.co/nHMHIdZmgu

[marvelbiosciences @marvelbiosci]

Scientists discover genetics behind leaky brain blood vessels in Rett syndrome

https://t.co/CWbC1awtk6

[marvelbiosciences @marvelbiosci]

Marvel planning trial to test fragile X treatment in healthy volunteers

https://t.co/V3c1bUU1pU

[marvelbiosciences @marvelbiosci]

Rett Syndrome Study Hints at Personalized Therapies

https://t.co/R5A859DAVU

[marvelbiosciences @marvelbiosci]

Marvel Biosciences announces participation and presentation at the 2nd Neuroscience Innovation Partnering & Licensing Summit in Boston, April 29, 2026, an important industry event that brings together leaders across the CNS and neuroscience ecosystem. PR: https://t.co/4LHcCcKt5a

[marvelbiosciences @marvelbiosci]

$MRVL Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders

Identification of two pediatric-friendly liquid formulations of lead compound, MB-204: preclinical data demonstrates strong oral bioavailability (<91%)

Full release: https://t.co/KP3ECWpPAP